ABOUT INFORMA PHARMA INTELLIGENCE

Informa Pharma Intelligence is the world’s leading provider of drug, device, company, clinical trial and market intelligence in the competitive pharma and medtech markets.

From early-stage portfolio decisions to clinical research and development and commercial planning and analysis, we offer a suite of complementary pharmaceutical business intelligence tools and solutions to support your business strategy.

All our services are delivered by an authoritative team of industry experts in key markets around the globe. And because our approach is interconnected, our analysts can give a broader perspective, identifying disruptive events, and in turn, helping you spot opportunities and mitigate risk.

Informa Pharma Intelligence is the trusted partner of more than 3,000 companies including the top 50 pharma firms and top 10 contract research organizations.

CONTACT INFORMATION

Informa Pharma Intelligence

5 Howick Place

London, SW1P 1WG

UNITED KINGDOM

Phone: 07787666701

Contact: Steven Horlock

FEATURED ARTICLES

  • New government disclosure regulations are emerging. Regulations from public health organizations around the globe have increased administrative compliance tasks and driven up the consequences of noncompliance. 

  • Discover the current state of innovation in Europe, from pipeline constitution to emerging drug modalities, R&D alliances to financing trends.

  • This year’s Roundup focuses on Phase I–III clinical trials initiated in 2021 across all therapeutic areas. The significant growth in 2021 trials results from approaches used in response to the pandemic, such as decentralized trials, innovative recruitment strategies, and greater patient engagement.

  • During 2012- 2021, APAC became a hotspot for clinical trials, with trial activity trending upwards and eventually contributing almost half of the entire global clinical trial activity in 2021. Explore the driving forces and unique differentiators among each location within this region.

  • From decentralized trials to real world data, take a look at top trends, their impact on patient enrollment and more, as well as ways to stay ahead of the curve.

  • From making sites inaccessible to the unprecedented development of vaccines, COVID-19 has permanently changed the nature of clinical research. This white paper assesses how well industry R&D has performed and what, if any, lessons have been learned.

  • The COVID-19 pandemic continued to reshape the clinical trials landscape in 2021. Trialtrove recorded 4,109 industry-sponsored clinical trials from Phase I through to Phase III/IV that either reached completed status or reported primary endpoints, an 8.8% annual increase.

  • See the industry’s NAS success stories: new chemical or biological entities where the active ingredient had received no prior approval for human use. 

  • Citeline Study Feasibility is a predictive analytics solution designed to help sponsors select the right countries, sites and investigators, minimizing startup time. It is powered by machine-learning (ML) algorithms trained on industry gold-standard datasets.

  • This white paper focuses on clinical trials, aligning the latest trends in rare disease R&D viewed through the lens of gold-standard clinical intelligence. From this emerges practical recommendations regarding clinical trial design, stakeholder engagement, and patient recruitment.

  • One way sponsors can eliminate barriers and incorporate the patient voice in the clinical trial process is by partnering with patient advocacy organizations. Discover the equally important roles that education and communication play. 

  • Three pressing issues stand out and require the collaborative efforts of the biopharma industry to slow the pandemic, reduce deaths and hospitalizations, and return life to something resembles normality: understanding long COVID, growing the arsenal of anti-infectives and tackling virus variants.

  • Advance planning is the key to streamlining plain language summaries (PLS). With the EMA’s new Clinical Trial Information System (CTIS) on track to launch Jan. 31, sponsors would be well advised to prepare their PLS now. Here’s how.

  • Patients look to disease and advocacy groups as trusted resources, particularly when it comes to clinical trials. These groups have a responsibility to provide accurate, up-to-date clinical trial information — and counter misinformation. Communication is key.

  • Utilizing the gold-standard clinical trials intelligence database Trialtrove, this analysis delves into the sponsors, diseases, and types of trials taking place in China, and considers the drivers shaping the present-day landscape. As the statistics show, the real explosion in clinical activity in China may be just starting.

  • In this year’s analysis, we dissect data from all Phase I–III clinical trials that started in a year dominated by COVID-19. The report reveals trends, discusses the industry’s evolution, highlights shifts in drug development strategies, and examines the emergence of (or declined activity in) key markets.

  • Do you suffer from text neck? Learn what it is, along with the causes, symptoms, and treatments for this common condition, with detailed images showing the biomechanics and anatomical structures involved. 
     

  • The COVID-19 pandemic created delays for trials that were planned for completion in 2020 and directly contributed towards trial terminations. Despite this, more diseases, and more indications outside of oncology, achieved at least 25 successful trials. Read the full report.

  • Are you ready for the new Clinical Trial Information System (CTIS)? With European Clinical Trial Regulation (EU-CTR) 536/2014 set to go into effect in January, all stakeholders will be required to submit study information through CTIS. Be prepared with these best practices.

  • Discover how even greater time and cost savings can be realized when study feasibility is applied to trials in niche patient populations, where limited availability of data precludes conventional approaches